TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$50 Million

Tenaya Therapeutics, Inc.

Underwritten Offering

Bookrunner, February 2024

Tenaya Therapeutics, Inc.

Tenaya Therapeutics, Inc. (“Tenaya” or the “Company”) is a clinical-stage biotechnology company committed to discovering, developing and delivering potentially curative therapies that address the underlying drivers of heart disease. Leveraging its integrated and interrelated Gene Therapy, Cellular Regeneration and Precision Medicine platforms and proprietary core capabilities, the Company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. Tenaya’s lead product candidates are: TN-201, a gene therapy for myosin binding protein C3 (MYBPC3)-associated hypertrophic cardiomyopathy (HCM), TN-401, a gene therapy for plakophilin 2 (PKP2)-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), and TN-301, a small molecule for heart failure with preserved ejection fraction (HFpEF).